Trulieve Reports 10% Revenue Decline and $405.4 Million Net Loss in Q2 2026

Trulieve Cannabis Corp. reported a significant decline in financial performance for the second quarter of 2026, with revenues totaling $270.9 million, down 10% from $302.1 million in the same period last year. The company attributed this decrease primarily to the Deconsolidation Transaction involving its former subsidiary, Harvest Enterprises, which ceased to be a consolidated entity on June 3, 2026. The net loss from continuing operations for the quarter was $405.4 million, a stark contrast to a profit of $15.8 million in the prior year, largely due to a $403.3 million loss recognized from the deconsolidation.

In terms of operational metrics, Trulieve's cost of goods sold decreased to $108.7 million from $119.2 million year-over-year, resulting in a gross profit of $162.3 million, down from $182.9 million. The gross profit margin remained relatively stable at 59.9%, compared to 60.6% in the previous year. Selling, general, and administrative expenses slightly increased to $101.8 million, reflecting costs associated with the deconsolidation. The company also reported a net loss attributable to common shareholders of $406.0 million for the quarter, translating to a loss per share of $2.10.

Strategically, Trulieve has been focusing on expanding its operations and enhancing its market presence. As of June 30, 2026, the company operated 206 dispensaries across four states, including Florida, Pennsylvania, West Virginia, and Georgia. The company is also pursuing a conditional approval for a dispensing organization license in Texas, which could further enhance its market footprint. The Deconsolidation Transaction has allowed Trulieve to retain a non-controlling investment in Harvest, which it now accounts for under the equity method, reflecting a shift in its operational strategy.

The company’s cash and cash equivalents increased to $325.4 million as of June 30, 2026, up from $255.5 million at the end of 2025, indicating a strong liquidity position despite the operational challenges. Trulieve's management expressed confidence in its ability to meet anticipated cash requirements over the next 12 months, primarily through cash generated from operations and potential debt or equity financing. The company is also actively working on regulatory compliance following the federal rescheduling of medical marijuana, which could further bolster its operational framework.

Looking ahead, Trulieve anticipates continued challenges in revenue generation due to pricing pressures in mature markets, but expects growth opportunities in emerging markets like Ohio and Texas. The company remains committed to enhancing its product offerings and customer experience, aiming to solidify its position as a leading player in the medical cannabis sector.